NR4A1 and breast cancer: 158 of 344 Swiss patients randomized in the IBCSG BIG VIII and IX trials with G2 hormone receptor-positive and Her2-negative breast cancer and with available tumor tissue in paraffin blocks were included in this study (Fig. 1).